Cardioprotector Activity of an Esteroidal Saponin: A Scientific and Technological Prospection.
BACKGROUND
Cardiovascular diseases are a group of disorders of the heart and blood vessels that account for a major cause of premature death worldwide. Diosgenin saponin is a steroid for therapeutic application in different clinical settings such as cardiovascular diseases, hyperglycemia and dyslipidemia control, antimicrobial, anti-viral and anti-inflammatory agent. The aim of the study was to conduct a systematic review of Diosgenin, its pharmaceutical applications and perspectives on the application in the cardiovascular system diseases.


METHODS
Periodic basis ScienceDirect, PubMed and Virtual Health Library were used as well as the European Office of the technological bases Patent Office, World Intellectual Property Organization, the Office US Patent and Trademark Office and the Brazilian database National Institute of Industrial Property. The keywords used were Diosgenin, cardiovascular system, hypertension, atherosclerosis and dyslipidemia and their correlations in English and Portuguese, with publications from January 2010 to June 2015.


RESULTS
After analysis of the technological and scientific bases, the results show that there is a limited number of patents showing that the Diosgenin action on the cardiovascular system is centered in the areas for chemical studies of steroid Diosgenin. In the scientific basis, the results show that there is an interesting Diosgenin action on the cardiovascular system.


CONCLUSIONS
Therefore, studies with Diosgenin are promising on account of its significant pharmacological potential from scientific and technological viewpoints, reaching for a technology transfer to generate economic and industrial growth.
Michely Laiany Vieira
ML
Moura
Aldeidia
A
Pereira de Oliveira
Federal University of Piaui Post-Graduation Program in Pharmaceutical Science, CEP 64048-901, Teresina, Piaui. Brazil.
Hercília Maria Lins
HM
Rolim
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D050197:Atherosclerosis / Q000188:drug therapy* / Q000503:physiopathology; D002316:Cardiotonic Agents / Q000494:pharmacology*; D004144:Diosgenin / Q000494:pharmacology*; D004195:Disease Models, Animal; D050171:Dyslipidemias / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D051379:Mice; D010330:Patents as Topic; D051381:Rats; D012503:Saponins / Q000494:pharmacology
D000893:Anti-Inflammatory Agents; D002316:Cardiotonic Agents; D012503:Saponins; D004144:Diosgenin
Cardiovascular system; Diosgenin; atherosclerosis; dyslipidemia; hypertension; nanotechnology; saponin